Genistein Derivatization - From a Dietary Supplement to a Pharmaceutical Agent

Aleksandra Rusin¹ and Zdzisław Krawczyk¹,²

¹Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch
²Department of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Silesian University of Technology, Poland

1. Introduction

Many soy supplements in the market focus on estrogen and antioxidant properties of isoflavonoid, genistein. Due to the structural similarity to estrogen and binding to estrogen receptor, genistein is often referred to as a phyto-hormone or a dietary estrogen from soy. Target applications of isoflavone-enriched whole soy concentrates include natural hormonal replacement therapy and women’s health products (Knight & Eden, 1996; Messina, 1995). However, beneficial effect of genistein on human health extends to the prevention of cancer, cardiovascular events, diabetes, and incidence of inflammatory diseases and management of some metabolic diseases (Birt et al., 2001, Kurzer, 2002; Rimbach et al., 2008; Węgrzyn et al., 2010).

The view of genistein as a safe and healthy food supplement is not entirely clear, however. Although most studies show no risk of high consumption of soy-based products for human growth, development or reproduction, there are some data urging caution in genistein overdose. Genistein is implicated as a possible cause of infertility and liver disease in some animal species. Consumption of genistein-rich food and supplements during pregnancy have been suggested to increase the risk of infant leukemias (Hengstler et al., 2002). In addition, experimental data showing stimulatory effect of genistein on proliferation of some breast cancer cells lines raise the problem of safety of genistein supplementation in women with diagnosed breast cancer (Lavigne et al., 2008).

Despite the controversies about safety and benefits of soy food supplementation, the pleiotropic activity of genistein, resulting from its interaction with numerous molecular targets, along with the possibility of chemical derivatization of a molecule place genistein among leading compounds for drug development.

This chapter deals with two main issues: (1) describes the main molecular targets affected by genistein and indicates alterations in signaling pathways, revealed by global gene profiling analyses, and (2) delineates the relevant examples of genistein derivatives synthesized with aim to obtain compounds exhibiting improved pharmacological activity, increased affinity
to molecular targets or altered mode of action as compared to the parent drug. The clinical utility of genistein-based pharmaceuticals is also discussed.

2. Molecular targets affected by genistein

Genistein is known for its pleiotropic effects, mediated by alteration of the activity of key enzymes involved in cell signaling, and by changes of the expression of the genes involved in various physiological processes. To the large group of genistein targets new proteins discovered with use of potent computational methods have joined recently. The interplay between different signaling pathways is extensively studied; however, exact molecular mechanisms have not been clearly defined yet.

2.1 Binding of genistein to different proteins

The proteins affected directly by genistein belong to many families. Among them are nuclear receptors, tyrosine-specific protein kinases, topoisomerases, ABC transporters and transport proteins present in the bloodstream (Tab. 1).

Nuclear receptors are members of a large family of transcription factors activated by binding of a ligand and regulating gene expression underlying a plethora of physiological and pathological states. Genistein binds to and activates estrogen receptors, peroxisome-proliferators activated receptors, liver X receptors and estrogen related receptors.

It was recognized very early that the chemical structure of genistein bears strong similarity to 17β-estradiol, and that genistein binds to estrogen receptors (ER) and to sex hormone-binding globulins (Klinge, 2000; Kuiper et al., 1998; Kurzer, 2002). A functional interaction of genistein with estrogen receptors, leading to stimulation of ER responsive genes was confirmed in experiments in vitro (Birt et al., 2001; Kostelac et al., 2003). There are two isoforms of estrogen receptor, ERα and ERβ, differentially expressed in tissues and exhibiting different biological functions. The hydrophobic ligand-binding cavity displays 53% of similarity between two isoforms (Manas et al., 2004). This pocket contains 12 α-helices and two β-sheets, connected by several short straight fragments. Inside a ligand binding cavity the ligand molecule is oriented with hydrogen bonding at the ends and hydrophobic van der Waals contacts along the body of the hormone. In the ERα functionally important polar amino acids in the binding pocket include: Glu-353, Arg-394, and His-524 (Tanenbaum et al., 1998). These aminoacids interact with 7 and 4’ OH groups of genistein. Several other amino acid residues create hydrophobic bonds essential for stabilizing the nonpolar elements of the ligand ring structure. Genistein is regarded as an agonist of ERα. Although ligand binding domain sequence and structure in ERβ is very similar to ERα and stabilization of a ligand occurs due to analogous hydrogen bonding with the side chains of Glu-305, Arg-346 and His-475 (Fig. 1), genistein binds to this form with higher affinity than to ERα (Manas et al., 2004). The position of the ligand in both receptor types is similar, but the volume of a cavity is smaller in ERβ, and genistein is bound more tightly in the cavity. Despite the higher affinity to ERβ than ERα, genistein is only partial agonist of ERβ. The explanation may be derived from the different conformations of a ligand-bound state of ERα and ERβ. Hormone-dependent activation of a receptor is a result of the movement of helix 12 from one position to another. The positional variability of this substructure appears to be a critical attribute of the ER receptors in their variable response to different ligands (Pike et al., 1999).
Recently it was shown that proteins constituting the family of estrogen related receptors (ERRs) are also able to bind genistein (Suetsugi et al., 2003). Although they display similarity to estrogen receptors, they do not bind estrogens. ERRs are referred to as orphan receptors, because no endogenous ligands required for their activity have been identified so far. The ligand-binding pockets of ERRs are very small (about half size of ERα) and partially filled with the aromatic bulky side chains of aminoacids forming the cavity, what is supposed to mimick the ligand-bound state inducing constitutive activity of the receptor. Surprisingly, genistein is a strong agonist of those receptors, augmenting their basal activity. Docking results showed that genistein, due to the small size of the cavity, is tightly packed and deeply docked into the ligand-binding site (Suetsugi et al., 2003) (Fig. 2).

Fig. 1. The ligand-binding cavity in the genistein bound human estrogen receptor β. 4’OH group of genistein forms hydrogen bonds with the Glu-305, the Arg-346 and a water molecule; 7OH group forms hydrogen bond with His-475. Reprinted by permission from Macmillan Publishers Ltd: Pike et al. 1999, EMBO Journal Vol.18, No.17, 4608–4618, Copyright 1999.

Fig. 2. The binding pocket of genistein-bound ERRα. 7OH group of genistein forms hydrogen bonds with the glutamate in helix 3, the arginine in helix 5, and a water molecule; 4’OH group forms hydrogen bond with H398. Adapted and reprinted by permission from American Association for Cancer Research, Suetsugi et al. 2003, Molecular Cancer Research Vol.1, No.13, 981-991.
Other members of nuclear receptor family activated by genistein are peroxisome proliferators-activated receptor γ (PPARγ) (Dang et al., 2003) and PPARα (Kim et al., 2004; Kim et al., 2005). The main role of PPARγ is to control the genes involved in adipocyte differentiation and lipid storage. The structure of ligand binding domain in the PPARγ is similar to both PPARα and PPARγ, and consists of 12 helices arranged in an antiparallel helix sandwich, and additional 3-stranded antiparallel β sheet (Cronet et al., 2001). Docking studies, supported by the functional assay, characterized genistein as a full PPARγ agonist (Salam et al., 2008). Subsequent studies shown, that agonistic action of genistein on PPARγ stimulates adipogenesis (Relic et al., 2009). It is worth to keep in mind that genistein concurrently activates two different transcriptional factors, ERs and PPARγ, which have opposite effects on osteogenesis or adipogenesis. Thus, genistein as an agonist of both receptors may affect the balance between activated ERs and PPARγ, which determines the final effects on osteogenesis and adipogenesis.

Very weak binding of genistein to androgen receptor (AR) was reported by Becitic et al. (2004). However, the inhibition of specific androgen binding was less than 25% at 1000-fold higher concentration of genistein (1 μM) in a radioligand-binding assay. Moreover, this weak binding did not influenced AR transcriptional activity measured by a reporter gene assay in PC-3 and DU 145 cells. The authors concluded, that genistein influence the expression of AR dependent genes indirectly, by down-regulation of AR.

Another group of enzymes binding genistein are proteins, which share in their structure the consensus sequence for ATP binding, such as tyrosine kinesis, topoisomerases, ABC transporters, and ion channels. Although genistein does not resemble ATP, its binding is competitive to ATP.

Historically, the first proteins affected by genistein were protein tyrosine kinases (PTK) (Akiyama et al., 1987). Suppression of PTKs is thought to occur due to genistein binding with a common, highly conservative sequence at, or near to, the ATP-binding domain (Markovits et al., 1989; Akiyama et al., 1987). Genistein is a competitive inhibitor of ATP in a number of tyrosine kinases that utilize the G-X-G-X-X-G consensus for ATP binding (Akiyama et al., 1987).

To another group of proteins affected by genistein belong hexose transporters. The 12 transmembrane α-helical domains of the monomeric GLUT protein form a central water-filled pore, facilitating glucose transport. Vera et al. (1996) found that genistein inhibited transport of substrates by the GLUT1, blocking its ATP-binding domains. Similar mechanism of glucose uptake inhibition by genistein occurs in GLUT4 (Bazuine et al., 2005). Exact binding mode of genistein in GLUT1 is not known. It is hypothesized, that genistein, binding to the cytoplasmic surface of GLUT1, uses the sequences of close homologies to the sequences in the ligand-binding cavity of estrogen receptors (Afzal et al., 2002) (Fig. 3). These domains are in close vicinity or partially overlap the ATP-binding sites, so binding of estrogen, tamoxifen and genistein may competitively inhibit ATP binding.

The inhibition of topoisomerases by genistein is thought to be mediated by its binding to N-terminal ATP-binding motif. Topoisomerase II maintains the integrity of the cleaved DNA by forming covalent bonds with each newly created 5’-phosphate termini of the cleaved DNA segment. This transfer of phosphodiester bonds from DNA to topoisomerase II is similar to the autophosphorylation reaction of tyrosine kinases, where the enzyme forms a bond between its tyrosine and the phosphate group of ATP. Eucaryotic topoisomerase IIα has two consensus ATP-binding motifs. Only Walker A site (residues 161-166 in human topoisomerase IIα) is utilized for ATP binding in the eukaryotic type II enzyme. The Walker B site (residues 472-477), located near the region of the enzyme, in close proximity to the site
of DNA cleavage and ligation, has no known function for topoisomerase activity, but its consensus sequence (G-X-G-X-X-G), is the same, as the ATP-binding consensus sequence in a number of tyrosine kinases (Markowitz et al., 1989). Probably, this non-functional consensus site, common with protein kinases is the sequence of topoisomerase IIα, which binds genistein (Bandele & Osheroff 2007).

Fig. 3. Structure of GLUT1. A. Two-dimensional model of GLUT1 with Walker ATP-binding domains (red), and homologies to ERβ (turquoise, violet, blue and yellow). B. Close view of H bonding interactions of genistein (dark red) with His and Arg of GLUT1. Colours on A and B match each other. Reproduced with permission, from Afzal et al. 2002, Biochemical Journal Vol. 365, No.3, 1707-1719, © the Biochemical Society.

Cystic fibrosis transmembrane conductance regulator (CFTR) belongs to ABC transporter-class ion channels, and transports chloride through epithelial cells membranes. Potentiation of Cl⁻ ion efflux through CFTR by genistein is thought to result from interaction of the isoflavonoid with one of two ATP-binding sites in the regulatory nucleotide-binding domains (NBD) of a protein. In CFTR, the membrane spanning domains form a pathway for passive anion flow that is gated by cycles of ATP binding and hydrolysis (Hwang & Sheppard 2009) (Fig. 4). It is established that ATP hydrolysis at ATP-binding site 2 is responsible for a rapid closure of the gate opened by ATP (Chen & Hwang, 2008; Gadsby et al., 2006). Competitive binding of genistein to the second ATP-binding site disables channel gating (Wang et al., 1998), what means that potentiation of CFTR Cl⁻ current is a result of the channel locking by genistein in a stable open state. Exact mode of genistein binding to CFTR is unknown, however docking studies indicate several putative binding sites in the protein (Huang et al, 2009) (Fig. 4B).

The next group of proteins binding genistein are blood proteins. Binding of genistein to human sex hormone-binding proteins (hSHBG) is reversible and competitive for both [3H]testosterone and [3H]17b-estradiol (Dechaud et al., 1999). Genisten binding to hSHBG may influence its bioavailability to cell tissues, and displace endogenous sex steroid hormones from hSHBG binding sites.

Human serum albumin (HSA) with high affinity binding sites is a major transporter for delivering several endogenous compounds and drugs in vivo. Structural analysis showed that genistein binds to HSA via polypeptide polar groups (Mandeville et al., 2009). Binding of genistein to albumins is reversible, rapid and the concentration of unbound isoflavone is in an equilibrium state.

It is worth to note, that hemoglobin is able to bind genistein, what makes this most abundant protein of blood, important for genistein transportation, distribution and storage (Yuan et al., 2008). Transthyretin (TTR) is a tetrameric β-sheet-rich transporter protein involved to some extent in the transport of thyroid hormone, thyroxine. TTR binds genistein via the thyroxine (T4)
binding sites. TTR has two identical funnel-shaped thyroxine-binding sites located at the dimer–dimer interface (Fig. 5). Binding of thyroxine stabilizes native, tetrameric state, whereas dissociation of the hormone promotes dissociation of the protein to monomers, and their abnormal aggregation, observed in human amyloid diseases. Since only 1% of TTR is bound to thyroxine, small molecules, such as genistein may help to stabilize the tetrameric structure. Genistein is known to potently inhibit TTR amyloid fibril formation (Green et al., 2005). In TTR, the mode of genistein binding is sequential, with negative cooperativity observed. Binding of the first genistein molecule to TTR generates allosteric adjustment of conformation in the second genistein binding site. The most stable conformation of TTR protein is observed when two molecules of genistein are bound to the tetramer (Trivella et al., 2010).

Fig. 4. The simplified model of CFTR Cl− channel opening. A. closed state, B. open state, C. stable open state, forced by genistein (dark blue molecule), which blocks ATP-binding site 2. IN and OUT denote the intra- and extracellular sides of the membrane, respectively. NBD1 - turquoise, NBD2 - green, site 1 and site 2 – ATP-binding sites. D. A stereo view of five putative binding sites of genistein to human CFTR. Ball-and-stick molecules of genistein are shown in blue, and the ATP in yellow. Residues are important for interacting with genistein are in magenta. A and B - Reproduced with permission from John Wiley and Sons, Hwang & Sheppard 2009, Journal of Physiology, Vol.587, No.10, 2151–2161, D - Reprinted from Journal of Molecular Graphics and Modelling, Vol.27, No. 7, Huang et al. 2009, Pages 822-828, Copyright (2009), with permission from Elsevier.

Fig. 5. Structure of transthyretin. A. Schematic representation of the tetrameric structure of TTR depicting the two thyroxine-binding sites with two molecules of genistein stabilizing the tetramer. Modified from Green et al., 2005, with permission. Copyright (2005) National Academy of Sciences, U.S.A.
There are also many intracellular proteins which functions are affected upon genistein binding listed in the Tab. 1., which does not fit any group described above, such as ornithine decarboxylase, aromatase CYP19 or tubulin. Cytoskeleton protein, tubulin binds genistein at ANS-binding site, what leads to depolymerization of microtubules (Mukherjee et al., 2010).

<table>
<thead>
<tr>
<th>Classess of proteins binding genistein</th>
<th>Proteins</th>
<th>Type of influence on a protein activity</th>
<th>Binding affinity (Ki) or 50 % inhibitory concentration (IC50)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogen receptors</td>
<td>Erα</td>
<td>Agonist</td>
<td>Ki=370 nM IC50=1.97-14 µM</td>
<td>Matsuda et al., 2001, Güngör et al., 2006, Kostelac et al., 2003</td>
</tr>
<tr>
<td></td>
<td>ERβ</td>
<td>Partial agonist</td>
<td>Ki=24nM; IC50=1.3-395 nM</td>
<td>Pike et al., 1999, Matsuda et al., 2001, Chesworth et al., 2005; Mewshaw et al., 2007</td>
</tr>
<tr>
<td>Estrogen related receptors</td>
<td>ERRα</td>
<td>Agonist</td>
<td>IC50=2.4 µM</td>
<td>Suetsugi et al., 2003</td>
</tr>
<tr>
<td></td>
<td>ERRβ</td>
<td>Agonist</td>
<td>IC50&gt;10 µM</td>
<td>Suetsugi et al., 2003</td>
</tr>
<tr>
<td></td>
<td>ERRγ</td>
<td>Agonist</td>
<td>IC50&gt;10 µM</td>
<td>Suetsugi et al., 2003</td>
</tr>
<tr>
<td>Peroxisome proliferator activator receptor</td>
<td>PPARγ</td>
<td>Agonist</td>
<td>Ki=5.7 µM IC50=16.7 µM</td>
<td>Dang et al., 2003, Salam et al., 2008</td>
</tr>
<tr>
<td>Androgen receptor</td>
<td>AR</td>
<td>No transcription activation</td>
<td>Ki&gt;&gt;1 µM</td>
<td>Bektic et al., 2004</td>
</tr>
<tr>
<td>Liver X receptor</td>
<td>LXR-α</td>
<td>Agonist</td>
<td>IC50=31 µM</td>
<td>Dodo et al., 2008</td>
</tr>
<tr>
<td></td>
<td>LXR-β</td>
<td>Agonist</td>
<td>IC50=22 µM</td>
<td>Dodo et al., 2008</td>
</tr>
<tr>
<td>Tyrosine kinases</td>
<td>EGFR</td>
<td>Inhibitor</td>
<td>IC50=22 µM</td>
<td>Akiyama et al., 1987</td>
</tr>
<tr>
<td></td>
<td>Pp60 v-src</td>
<td>Inhibitor</td>
<td>IC50=26 µM</td>
<td>Akiyama et al., 1987</td>
</tr>
<tr>
<td></td>
<td>Pp110 gag-fes</td>
<td>Inhibitor</td>
<td>IC50=24 µM</td>
<td>Akiyama et al., 1987</td>
</tr>
<tr>
<td></td>
<td>MEK4</td>
<td>Inhibitor</td>
<td>IC50=0.4 µM</td>
<td>Xu et al., 2009</td>
</tr>
<tr>
<td></td>
<td>ABL</td>
<td>Inhibitor</td>
<td>IC50=10 µM</td>
<td>Traxler et al., 1995</td>
</tr>
<tr>
<td></td>
<td>Protein kinase C</td>
<td>Inhibitor</td>
<td>IC50=15 µM</td>
<td>Traxler et al., 1995</td>
</tr>
<tr>
<td></td>
<td>Tyrosine Kinase Syk</td>
<td>Inhibitor</td>
<td>IC50=39 µM</td>
<td>Xie et al, 2009</td>
</tr>
<tr>
<td>FGF receptor 1</td>
<td>FGF1</td>
<td>Inhibitor</td>
<td>IC50&lt;25 µM</td>
<td>Rao, 1997</td>
</tr>
<tr>
<td>Ion channels</td>
<td>CFTR</td>
<td>Potentiator</td>
<td>Ki=1.8 µM</td>
<td>Melani et al., 2010</td>
</tr>
<tr>
<td>Classess of proteins binding genistein</td>
<td>Proteins</td>
<td>Type of influence on a protein activity</td>
<td>Binding affinity (Ki) or 50 % inhibitory concentration (IC50)</td>
<td>Source</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>----------</td>
<td>----------------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Glucose transporters</td>
<td>GLUT1</td>
<td>Inhibitor</td>
<td>Ki=4-12 μM</td>
<td>Afzal et al., 2002; Vera et al. 1996</td>
</tr>
<tr>
<td></td>
<td>GLUT4</td>
<td>Inhibitor</td>
<td>IC50=20 μM</td>
<td>Bazuine et al., 2005</td>
</tr>
<tr>
<td>MDR proteins</td>
<td>ABC G2</td>
<td>Substrate</td>
<td>n.a.</td>
<td>Imai et al., 2004; Zhang et al., 2004; Perez et al., 2009</td>
</tr>
<tr>
<td>Topoisomerase I</td>
<td>Topo I</td>
<td>Inhibitor</td>
<td>n.a.</td>
<td>Okura et al., 1988</td>
</tr>
<tr>
<td>Topoisomerase II</td>
<td>Topo II α</td>
<td>Inhibitor</td>
<td>IC50&lt;30 μM</td>
<td>Bandele &amp; Osheroff, 2007</td>
</tr>
<tr>
<td></td>
<td>Topo II β</td>
<td>Inhibitor</td>
<td>IC50=30 μM</td>
<td>Constantinou et al., 1995; Okura et al., 1988; Markovitz et al., 1989</td>
</tr>
<tr>
<td></td>
<td>Bacterial gyrase</td>
<td>Inhibitor</td>
<td>IC50&gt;200 μM</td>
<td>Bernard et al., 1997</td>
</tr>
<tr>
<td></td>
<td>Bacterial topo IV</td>
<td>Inhibitor</td>
<td>IC50=93 μM</td>
<td>Bernard et al., 1997</td>
</tr>
<tr>
<td>Adenosine receptors</td>
<td>A1</td>
<td>Inhibitor</td>
<td>IC50=2.6 μM</td>
<td>Schulte &amp; Fredholm, 2002</td>
</tr>
<tr>
<td></td>
<td>A2A</td>
<td>Inhibitor</td>
<td>IC50=15.3 μM</td>
<td>Schulte &amp; Fredholm, 2002</td>
</tr>
<tr>
<td>Aromatase</td>
<td>Cyp 19</td>
<td>Inhibitor</td>
<td>Ki=100 μM</td>
<td>Paoletta et al., 2008</td>
</tr>
<tr>
<td>Tubulin</td>
<td>Tubulin</td>
<td>Polymerization inhibitor</td>
<td>Ki=20 μM IC50&gt;87 μM</td>
<td>Mukherjee et al., 2010</td>
</tr>
<tr>
<td>Ornithine decarboxylase</td>
<td>ODC</td>
<td>Inhibitor</td>
<td>&gt;10 μM</td>
<td>Fang &amp; Cassida, 1999</td>
</tr>
<tr>
<td>Sex hormone-binding globulin</td>
<td>hSHBG</td>
<td>Competitive binding to testosterone and estradiol</td>
<td>$K_a=1.7 \times 10^5$ M$^{-1}$ (Testosterone) $K_a=6.3 \times 10^5$ M$^{-1}$ (estradiol)</td>
<td>Dechaud et al., 1999</td>
</tr>
<tr>
<td>Albumins</td>
<td>HAS</td>
<td></td>
<td>$K=2.4 \times 10^4$ M$^{-1}$</td>
<td>Mandeville et al., 2009; Bian et al. 2004</td>
</tr>
<tr>
<td>Haemoglobin</td>
<td></td>
<td></td>
<td>n.a.</td>
<td>Yuan et al., 2008</td>
</tr>
<tr>
<td>Transthyretin</td>
<td>TTR</td>
<td>Competitor of T4</td>
<td>Ki=70nM</td>
<td>Radovic et al., 2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Stabilisator of a tetramer $K_{d1}=40$ nM, $K_{d2}=1.4$ μM</td>
<td>Green et al., 2005</td>
</tr>
</tbody>
</table>

Table 1. Proteins binding genistein and the type of influence on their activity
New efficient computer-assisted methods facilitate rapid identification of protein targets of potential drugs (Chen et al., 2003). INVDOCK is one of in silico techniques specifically applied to identification targets of medicinal plants ingredients and synthetic chemicals. It is based on ligand–protein inverse docking of a tested ligand to known ligand-binding pockets of the proteins from a 3D structural database. Many proteins indicated by the aid of INVDOCK as potential targets of genistein were previously confirmed or implicated by experiments. This approach allowed also indication of multiple new targets with therapeutic implications, able to bind genistein. Among them are: thymidylate synthetase, purine nucleoside phosphorylase, cyclophilin A, farnesyltransferase, guanylyl cyclase, carbonic anhydrase (cancer treatment), DNA polymerase, (cancer and Herpes viral infection), inosine dehydrogenase, purine nucleoside phosphorylase (Malaria), dihydrofolate reductase (leprosy), phospholipase A2 (inflammation), carbonic anhydrase I (hypertension and glaucoma), protein kinase C (cardiovascular disease).

From many studies on the oral bioavailability of genistein it is clear that in vivo plasma concentrations of genistein is 0.1–8 μM at a dose of 16 mg/kg of body weight (Bloedon et al., 2002; Setchell et al., 2001). Tab. 1. shows that the concentration of genistein, inhibiting or stimulating several potential targets, is much higher than its concentration in plasma, thus its physiological relevance is disputable. However, it might be possible, that under chronic exposure, even weak effects of genistein on molecular targets influence the overall physiological status.

2.2 Signalling pathways influenced by genistein in microarrays profiling
Specific changes in gene expression profiles brought about by the genistein treatment can occur either due to direct influence of the flavonoid on activity of transcription factors or to indirect compensatory homeostatic mechanisms. A global analysis of gene expression in response to a pleiotropic compound, such as genistein, in models of different organs under physiologic and disease conditions appears to be essential for understanding the molecular mechanisms of genistein action and seems to be advantageous approach in comparison to “gene-by-gene” studies. In this chapter we summarize the most important observations derived from transcryptomic, microarray-based studies aimed to identify gene sets influenced by genistein in normal and tumor tissues.

In general, microarray data published so far supports existing hypotheses on the mechanisms of action of genistein, both beneficial for human health (i.e. reduction of cancer risk, amelioration of postmenopausal syndrome and decrease of bone resorption in postmenopausal women, lipid metabolism, cardiovascular homeostasis) (Kim et al., 2005; Lee et al., 2007; Pie et al, 2006; Rice et al., 2007) and unfavorable (as estrogen-dependent cancer cell proliferation and adverse effects on the reproductive organs or involution of thymus and auto-immune disorders) (Lee et al., 2007; Naciff et al., 2002; Selvaraj et al., 2005). Those homeostasis-maintaining or homeostasis-affecting effects are often observed at low concentrations of genistein, essentially not exceeding 5 μM.

Functional categorization of genes affected by genistein on transcriptional level repeatedly indicates genes involved in cell growth, cell cycle, apoptosis, cell signals transduction, angiogenesis, tumor cell invasion and metastasis, cholesterol synthesis and lipid metabolism (Kim et al. 2005; Li et al., 2004; Li & Sarkar, 2002; Niculescu et al., 2007; Pie et al., 2006; Rice et al., 2007; Selvaraj et al., 2005). Among the genes regulated by genistein is a group of genes with common mechanism of regulation by nuclear receptors: estrogen receptors (Selvaraj et al., 2005) and androgen receptor (Rice et al., 2007).
The papers comparing the expression profiles of cells treated with estradiol and genistein show a considerable overlap in the genes not only in reproductive organs, but also in other tissues influenced by estrogens. Among non-reproductive organs in which strong changes of expression profile occurred in estrogen receptor-dependent manner after treatment with genistein are bones (Pie et al., 2006), liver and adipose tissue (Kim et al., 2005), thymus (Selvaraj et al., 2005), lymphocytes (Niculescu et al., 2007), brain (Lyou et al., 2002), endothelial cells (Rimbach et al., 2008), cardiovascular system and muscles (Velders et al., 2010). It has to be noted that the expression profile influenced by high genistein uptake may not depend on genistein directly, but on the ability of individuals to metabolize genistein to equol (Niculescu et al., 2007).

The findings that dietary isoflavones may play a beneficial role in lipid and carbohydrate metabolism prompted the group of Kim et al. (2005) to perform cDNA microarray-based analysis in mice fed with high-fat diet (HFD) and supplemented with genistein. Mice fed the high-fat diet had abnormal lipid profiles, significantly greater body weight, and visceral fat accumulation and all these effects had been significantly reduced by genistein supplementation. Of much importance was also the observation that the expression of 84 genes affected by the high-fat diet was normalized by genistein. The expression of genes encoding enzymes of cholesterol biosynthesis, which decreased by at least 50% in the high-fat diet fed mice, returned to normal level as a result of genistein supplementation.

Pie et al. (2006) in their cDNA microarray study shown changes in the expression levels of bone metabolism-related genes, including those encoding calcitropic receptor, cytokines, growth factors and bone matrix proteins by genistein in ovariectomized mice. The study demonstrated that genistein prevented bone loss caused by estrogen deficiency without substantially affecting the uterus.

Many studies have correlated the soy-rich diet with a decreased risk of developing hormone-dependent cancers, including breast and prostate cancer. The result of a study carried on HCC1395 cells line derived from an early-stage primary breast cancer showed that genistein dose-dependently decreased cell viability and inhibited the invasion potential (Lee et al., 2007). The gene expression profile revealed upregulation of some genes which inhibit invasion and metastasis and downregulation of genes promoting these processes, indicating that genistein-induced alternations of gene expression involving metastasis may be exploited for setting up chemopreventive and therapeutic strategies, particularly for early-stage breast cancer.

The oligo-microarray study by Lavigne et al. (2008) performed on MCF-F breast cancer cells shown that at physiologic concentration (1 or 5 μM) genistein elicited an expression pattern suggestive of increased mitogenic activity, and at pharmacological level (25 μM) it induced a pattern that likely contributes to increased apoptosis, decreased proliferation and decreased total cell number. These results strength former observations of biphasic response of certain cell lines to genistein.

Genistein is also a candidate prostate cancer preventive phytochemical. DNA microarray approach to examine the effects of genistein at concentrations within its physiologic range on global gene expression patterns in androgen-responsive cancer cells shown a concentration-dependent modulation of multiple cellular pathways that are important in prostate carcinogenesis. Interestingly, the androgen receptor (AR)-mediated pathways, in particular, appeared to be modulated by genistein at low concentrations. The regulation of AR-mediated pathways is potentially the most relevant chemopreventive mechanism for genistein administered at physiologic levels (Rice et al., 2007; Takahashi et al., 2004).
Selvaraj et al. (2005) gained insight into signaling pathways that regulate various stages of thymocyte maturation, dependent on estradiol and genistein, and found that the effects of both compounds were similar, although, genistein down regulated more genes than estradiol. Genistein was also shown to induce genes involved in apoptosis, which is a continuous process in the thymus undergoing active thymocyte selection, but at the same time it affected genes which may facilitate thymic release of autoimmune cells.

Microarrays were also used to get closer insight into the influence of genistein on female reproductive organs. The study performed by Naciff et al. (2002) revealed that prenatal exposure to genistein altered the fetal gene-expression pattern of the rat uterus and ovaries in a similar manner as exposition to the estrogenic compounds, such as 17-ethynylestradiol and bisphenol A. Toxicogenomic analysis with use of cDNA microarray applied to determination of testicular mRNA profiles was proposed as a useful tool for evaluation of delayed long-term effects after fetal or neonatal exposure of mice to genistein (Adachi et al., 2004). Although no morphological changes in the testes of genistein-treated mouse were observed, the authors indicated the gene (GeneBank accession No. W49392), which might be useful biological marker, in addition to ER$\alpha$ and AR, for predicting the effects of neonatal exposure to genistein or related compounds.

The long lasting effects of genistein may result from epigenetic influence of genistein on gene expression. The use of differential methylation hybridization (DMH) arrays for screening of the changes in the methylation status of the cytosine guanine dinucleotide (CpG) islands in the mouse genome shown important genistein–induced alterations (Day et al., 2002). The study showed that changes in the methylation pattern reflected potential of genistein for preventing the development of certain prostate and mammary cancers by maintaining a protective DNA methylation profile (Day et al., 2002). The ability of genistein to change the methylation status was observed in several other studies. Genistein was shown to partially demethylate the promoter of the GSTP1 tumor suppressor gene in MDA-MB-468 breast cancer line (King-Batoon et al., 2008). Another study shown the change of methylation status in mice prenatally exposed to genistein (Vanhees et al., 2011). Genistein exposure was associated with hypermethylation of certain repetitive elements, what coincided with a significant down-regulation of estrogen-responsive genes and genes involved in hematopoiesis in bone marrow cells of genistein-exposed mice.

In contrast to studies aiming to establish the role of genistein in homeostasis, the experiments designed for identification of gene expression profiles associated with a therapy, are often carried with suprapharmacological concentrations of a drug. In several studies of this kind, the most of affected genes were not dependent on hormonal regulation (Farivar et al., 2003; Lavigne et al., 2008; Li & Sarkar, 2002). The genes repeatedly found to be down regulated by genistein, were those involved mainly in signal transduction, oncogenesis, cell proliferation, protein phosphorylation and transcription. On the other hand, genistein up-regulated genes were related mainly to signal transduction, protein dephosphorylation, heat shock response, inactivation of mitogen-activated protein kinase (MAPK), apoptosis and cell cycle arrest. Among the genes regulated by genistein there was a number of genes regulated by tyrosine kinases inhibitors, like Gleevec (STI-571), lavendustin and herbimycin (Farivar et al., 2003). Studies on the evaluation of the global transcript profile changes performed on different models could be a valuable approach to determine the similarity in the mode of action of genistein derivatives, comparing to a parent compound. This approach may be useful for description of potential “druggable” targets and determination the safety profile of new compounds.
3. Synthetic derivatives of genistein and their potential medicinal applications

Many opportunities for derivatization of genistein, apparent from its structural formula encourage the synthesis of derivatives with improved pharmacological profile. The chemical basis describing functionalization of three phenolic groups at C-5, C-7 and C-4’ in typical O-acylation or O-alkylation reactions and skeletal modifications of genistein core, involving C–C bond formation is reviewed elsewhere (Rusin et al., 2010). Multiple examples of promising candidates intended to be used in therapy of different diseases are listed below. Among the diseases potentially treatable with the genistein derivatives are cancer, osteoporosis and metabolic disorders. Other suggested applications of genistein derivatives cover antibacterial and antiparasitic treatment. It must be noted, however, that most of presented derivatives have the status of experimental or investigational drugs.

3.1 Genistein derivatives for treatment of osteoporosis

Hormonal replacement therapy with synthetic estrogens was initially used for prevention of osteoporosis, however serious side effects of hormone replacement therapy stimulated the search for therapeutics, alternative to estrogens. Currently, among agents used in pharmacological prevention of osteoporosis are selective estrogen receptor modulators (SERMs), which function mainly as the antiresorptive agents (Reginster, 2011). Genistein, as a potential antosteoporotic dietary supplement draw attention for many years, mostly on the basis of epidemiological observations (Knight & Eden, 1996; Messina, 1995). Moreover, genistein was reckoned as a safe supplement, because it did not produce the harmful, estrogen-like effects in the uterus. However, the overall conclusions of genistein supplementation and retardation of bone loss are ambiguous. The randomized, double-blind, and placebo-controlled study by Marini et al. (2007) in osteopenic postmenopausal women revealed decreased bone resorption and increased bone formation in the genistein group. However, the results of this study permit only the conclusion that genistein may prevent progress from the mild disease - osteopenia, to its severe form – osteoporosis. Thus, genistein can be effective rather in chemoprevention than treatment of this disease.

For a long period of time the synthetic isoflavone, ipriflavone (7-isopropoxyisoflavone) was an attractive candidate for a bone-building agent, due to its anabolic, but not estrogenic activity (Gennari, 1997). Ipriflavone inhibits bone resorption mediated by osteoclasts and stimulates activity of osteoblast in cell cultures and in experimental models of osteoporosis in vivo. However, clinical studies shown no statistically significant difference in annual percentage change from baseline lumbar spine and bone mineral density between those given ipriflavone and those given calcium (Alexandersen et al., 2001).

In the matter of fact, there is no universal drug for osteoporosis and new treatments, comprising of both new drugs and new drug combinations are still under clinical investigations. Side effects of currently used drugs, which are their obvious drawbacks, accounts for directing attention to phytoestrogens such as isoflavones and their derivatives as more reliable drugs.

Genistein modification aiming enhancement of its antiosteoporetic properties is presented by Wang et al. (2005), who synthesized a number of genistein derivatives in which the C-7 or C-4’ hydroxyl groups were variously substituted. Among seventeen novel genistein derivatives the authors found five, which shown increased antiosteoporetic activity when compared to genistein, no acute toxicity and no stimulation of endometrium proliferation in...
Genistein Derivatization - From a Dietary Supplement to a Pharmaceutical Agent

265

mouse model of osteoporosis. The derivatives inhibiting bone loss during estrogen shortage contained the 2-hydroxyethylthio motif, which the authors assumed to be a key pharmacophore. The best results were observed for 4',5,7-tri[3-(2-hydroxyethylthio)propoxy] isoflavone.

Useful information on the structural features of genistein derivatives related to antosteopotic effects may be drown from the work of Zhang et al. (2008b). They discovered two natural derivatives of genistein in the stem bark of Erythrina variegata L.: 8-prenylgenistein and 6,8-diprenylgenistein stimulating osteoblastic proliferation, differentiation and mineralization in UMR 106 cells. These derivatives caused significant increase of alkaline phosphatase in cells treated by either 8-prenylgenistein or 6,8-diprenylgenistein for 48 h at the concentration of 10^{-10} M. A structure-activity relationship study indicates that prenylation at of genistein at C-8, but not at C-6, may increase its bone-protective effect.

Wang et al. (2007) presented the strategy, combining nitric oxide and genistein cooperation in inhibiting of a bone loss. The NO donor drugs effectively counteract bone mass loss occurring due to reduced rate of estrogen biosynthesis in postmenopausal women (Wimalawansa, 2000). What is particularly important, the NO donors not only slow down the rate of bone resorption, but also stimulate proliferation of osteoclasts (Hukkanen et al., 2003). In order to find a bifunctional derivative of genistein having both estrogenic properties and being an effective nitric oxide donor Wang et al. (2007) synthesized genistein 7,4'-(nitroxy) butyrate. Its NO-releasing capacity was studied in vitro using immature osteoblastic cell line MC3T3-E1 cells. It has been demonstrated that NO is released from the derivative less rapidly and for a longer time than from glycercyl trinitrate (GTN), the classical NO donor, routinely used in medical treatment (Wang et al., 2007). Using MTT assay and flow cytometry it was determined that the compound stimulated growth of MC3T3-E1 cells in a dose- and time-dependent manner, albeit the stimulation was weaker than that observed for an optimal concentration of estradiol. The measurements of the activity of a bone-specific isoform of alkaline phosphatase and the expression of osteocalcin, a specific marker for late osteoblast differentiation, as well as the rate of formation of calcific deposition revealed that the derivative stimulated osteoclast differentiation and mineralization more effectively than genistein, glycercyl trinitrate or combination of the two.

3.2 Genistein derivatives and hypertension

Genistein has been suggested to be protective in cardiovascular diseases. The study in vivo on spontaneously hypertensive rats had shown, that genistein reduced systolic blood pressure and enhanced endothelium-dependent aortic relaxation (Vera et al., 2007). Genistein reduced endothelial dysfunction due to increased endothelial nitric oxide synthase (eNOS) activity, associated with increased calmodulin-1 expression and decreased superoxide generation. Nitric oxide (NO) produced by eNOS is a well-known regulatory molecule involved in the modulation of contractility of vasculature thus maintaining vascular homeostasis (Miller & Megson, 2007).

Matsumoto et al. (2005) synthesized bifunctional derivative of genistein, which was aimed to inhibit tyrosine kinases, implicated in development of a hypertension, and release nitrogen oxide to enhance the effect. The authors synthesized two novel genistein derivatives 7-[(4-nitroxy)butyroyl]-genistein and 7-[(4nitrooxymethyl)-(alpha-methyl)phenylpropanyl]-genistein, and assessed their ability to relax rat endothelium-
denuded aortic strips. Both derivatives and genistein itself induced aortic relaxation in the following order: 7-[4(nitrooxy)methyl)-(alpha-methyl)phenylpropanoyl]-genistein > 7-[4-nitroxy)butyroyl]-genistein > genistein. The relaxation induced by the tested genistein derivatives was abolished by a guanylyl cyclase inhibitor, which proved, that genistein derivatives indeed acted as NO donors.

3.3 Genistein and its derivatives for treatment of cystic fibrosis
Genistein was shown to partially activate the defective chloride channels (cystic fibrosis transmembrane regulator, CFTR) associated with cystic fibrosis (CF). Genistein not only partially restored the CFTR activity but also augmented CFTR maturation and increased its localization at the cell surface (reviewed by Węgrzyn et al., 2010). Pre-clinical studies with genistein have provided a basis for clinical trials with CF patients, and a Phase II clinical study is currently underway. So far, genistein derivatives for potential treatment of cystic fibrosis have not been studied extensively. Galietta et al. (2001) generated a combinatorial compound library based on two lead compounds, flavones and benzo[c]quinoliziniums, which activate CFTR Cl\textsuperscript{−} conductance by direct interaction with the CFTR molecule. Among several novel derivatives they identified compounds with high potency to activate CFTR, 7,8-benzoflavones, containing features of both flavones and benzo[c]-quinoliziniums.

3.4 Derivatives with antimicrobial and antiparasitic activity
Antimicrobial properties of genistein are described in many papers, although the exact mechanism of this activity remains largely unknown (Hong et al., 2006; Ulanowska et al., 2006; Verdrengh et al., 2004). Cell survival studies suggest that genistein is a bacteriostatic, rather than a bactericidal agent (Ulanowska et al., 2007). There is a suggestion that antibacterial properties of genistein may be mediated by the stabilization of the covalent topoisomerase II-DNA cleavage complex (Verdrengh et al., 2004). The concentration of genistein necessary for bacterial growth retardation depends on the strain, but is regarded as relatively high (100 μM).

Zhang et al. (2008a) reported the derivatization of genistein leading to an increased antibacterial and antifungal activity. They prepared three series of derivatives in which the genistein ring system was linked to the heterocyclic moieties with 2-carbon, 3-carbon or 4-carbon spacers. Among these compounds, five exhibited good antibacterial activities, while one of them also showed notable antifungal activity. The activity of the mentioned derivatives was several fold higher than that of genistein.

The antimicrobial activity of genistein derivatives was also described by Li et al. (2008). They synthesized and tested 14 new deoxybenzoin derivatives of genistein and found that dimeric forms were generally more active than genistein or deoxybenzoins against selected microorganisms.

Several genistein derivatives are indicated for treatment of parasitic diseases. The potential use of genistein derivatives for anti-protozoan therapies were reported by Gargala et al. (2005) and Stachulsky et al. (2006), and, for anti-helminthic treatment by Naguleswaran et al. (2006). Gargala et al. (2005) screened fifty-two dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives for their influence on protozoa parasites life cycle: Neospora caninum, Sarcocystis neurona and Cryptosporidium parvum. Two agents selected in this screening: 3’-bromo and 4’-bromo genistein were tested as in Cryptosporidium parvum-
infected immunosuppressed gerbils. It was found, that these compounds more effectively abolished fecal microscopic oocyst shedding than two routinely used drugs, nitazoxanide and paromomycin.

Some of genistein derivatives described previously by Gargala (2005) were tested for inhibitory effects on the larval development of tapeworms *Echinococcus* sp. (Naguleswaran et al., 2006). The study shown, that 2’-bromo- and 6’-bromo genistein induced considerable damage in *E. granulosus* protoscolex. The above mentioned genistein derivatives are safe in terms of side effects caused by the estrogen receptor stimulation, because they do not bind to ER. These derivatives were shown to be selective for parasites, without antibacterial activity (Stachulsky et al., 2006), what allows to avoid the development of resistant bacterial strains.

### 3.5 Derivatives of genistein designed for anti-cancer therapy

Several strategies of genistein modification were applied in order to put its anticancer potential in use. Among them are targeted therapy and chemical modification of a molecule, so that to improve the interaction with molecular targets. Examples of those modifications are described below.

#### 3.5.1 Targeting genistein to cancer cells by conjugation with antibodies or peptide ligands

Major strategy of targeted therapy is to construct two-domain drugs, in which one domain recognizes the target cells, whereas the other one exerts a therapeutic activity. In order to selectively target genistein to intra-cellular kinase domain of epidermal growth factor receptor (EGFR) Uckun et al. (1998) obtained a conjugate of genistein with epidermal growth factor (EGF) via photochemical cross-linking. This conjugate was intended to target cancer cells overexpressing the epidermal growth factor receptor (EGFR). It was expected, that internalization of the conjugate should increase the intracellular concentration of genistein, and lead to efficient inhibition of the EGFR tyrosine kinase activity. In vitro studies confirmed strong proapoptotic activity of a conjugate in human breast cancer cells. (Uckun et al., 1998). Moreover SCID mice bearing tumors of human breast cancer cells (MDA-MB-231), treated intraperitoneally with the conjugate at 100 ug/day for 10 days showed significantly better survival as compared to mice treated with adriamycin, cyclophosphamide or methotrexate (Uckun et al., 1998).

A similar genistein targeting strategy, based on expected local increase of genistein concentration, was used for experimental treatment of leukemias (Ek et al., 1998). Genistein was conjugated to B43 antibody, recognizing the CD19 antigen, present on the surface of B lymphocytes and absent from plasma cells. CD19 is an adaptor protein for Lyn tyrosine kinase, amplifying signals transduction from nonreceptor Src tyrosine kinases. The study was performed on SCID mice bearing human acute lymphoblastic leukemia (ALL) or non-Hodkin’s lymphoma shown the conjugate to be more therapeutically effective than cytostatics routinely used for treatment of this kind of leukemias (Ek et al., 1998). In subsequent in vivo study performed on cynomolgus monkeys the conjugate administered intravenously shown no toxicity during long term observation (Messinger et al., 1998). These highly encouraging results inclined the authors to perform phase I clinical study (Uckun et al. 1999). The pilot study of B43-genistein in 15 patients with refractory B-lineage acute lymphoblastic leukemia shown that the conjugate was well tolerated by all patients with no life-threatening side effects. There was one durable complete remission and two transient responses.
More recently, Gentile et al. (2003) used genistein-monoclonal antibody approach to treat SW-620 and HT-29 colon cancer cells. The conjugate of genistein and 17.1A monoclonal antibody recognizing an epithelial membrane antigen expressed in colon cancer significantly inhibited cell growth \textit{in vitro} and \textit{in vivo}, and induced apoptosis.

### 3.5.2 Genistein as a vector selectively targeting cytostatic drugs to ER positive cancers

Interesting therapeutic approach is the use of genistein as a carrier, delivering drugs to cells expressing target recognized by this isoflavonoid. However, some difficulties must be overcome: (1) cytotoxic agent in a conjugate must not produce a loss of genistein binding to the target protein, (2) the target of a cytotoxic agent should be present in the subcellular structure which is likely to be achievable by a carrier, (3) the concentration of the receptor should be high, and its expression should not be down-regulated by a carrier.

An example of the above mentioned strategy was the use of genistein derivative, 6-carboxymethylgenistein (6CG) as a potential vector of a cytostatic drug, daunomycin to estrogen receptor expressing cells (Somjen et al., 2002; Somjen et al, 2003). Although the relative binding affinity of 6-CG was 0.1% to ER\textsubscript{b} and 0.01% to ER\textsubscript{a}, respectively as compared to the estradiol, it was shown that 6-CG activated the receptor, which translocated to the nucleus. Transactivation studies proved that 6-CG is a ligand of ERs. In the absence of estradiol 6-CG was found to be an agonist, while in the presence of estradiol it shown moderate antagonist activity for ER\textsubscript{a} (Somjen et al., 2003). The cytotoxicity of this conjugate was tested against H295R cells. At low daunomycin concentration (0.3-3nM) the cytotoxicity of a conjugate was 10 times higher than that of free drug, what indicated successful targeting of a conjugate. At higher concentration (30nM) the differences were less profound, and no differences were observed between daunomycin and its conjugate with 6-CG, what indicates that the toxicity was a result of non-specific, high intracellular concentration of daunomycin. The targeting of daunomycin conjugated to 6-CG via ER was also confirmed by the experiment with cells devoid of ER, where no differences in toxicity of a conjugate and free daunomycin were observed (Somjen et al., 2003).

### 3.5.3 Genistein derivatives designed for treatment of hormone dependent cancers

Endocrine treatment with selective estrogen-receptor modulators (SERMs), such as tamoxifen and raloxifene is of major therapeutic value in patients with estrogen-receptor positive tumors. Hormone-dependent breast cancer tumors contain estrogen receptors and tumor growth depends on estrogens. Tamoxifen, a partial nonsteroidal estrogen agonist, is a competitive inhibitor of estradiol, and the prototype of SERMs. However, after long exposure to the tamoxifen the resistance often develops, so designing and synthesis of new antiestrogens for treatment of breast cancer is of much importance.

Very promising trisubstituted derivatives of genistein able to bind estrogen receptor with low affinity were recently described by Davis et al. (2008). Several compounds were able to inhibit cell proliferation in a dose-dependent manner, and compounds containing the bulky 7-phenylmethoxy substituent were toxic for both hormone-dependant MCF-7 cells and hormone-independent MDA-MB-231 cells. Thus, the synthetic tri-substituted isoflavones act on multiple signaling pathways leading to activation of mechanisms of cell-death and ultimately affecting survival of breast cancer cells. A novel genistein derivative exhibiting significantly higher antiproliferative activity than the parent drug was recently obtained by
Kohen et al., (2007) by attaching an N-tert-butoxycarbonylo-1,6-diamino-hexane group to C2 of genistein. Although this novel genistein derivative did not show estrogenic activity, its antiproliferative activity was different in estrogen-sensitive cancer cell lines expressing ERα and ERβ mRNA at different ratios. The highest antiproliferative effect measured by radioactive thymidine incorporation was observed for an estrogen-sensitive colon cancer cell line (320DM), and the lowest for an ovarian cancer cell line (A2780). Interestingly, the genistein derivative was more toxic for cells that preferentially expressed mRNA for ERβ, relative to ERα.

3.5.4 High-throughput screening of genistein derivatives
In recent years a search for anticancer cytostatics based on the synthesis of libraries of differently substituted derivatives of genistein, followed by high-throughput screening in vitro has been intensified. Although it looks, to some extent, like trusting in serendipity, it allows to empirically find the most promising drug candidates. Such screening of more than 350 genistein analogues allowed to find several putative drugs for clinical development (Novogen). Among them was isoflavane phenoxodiol, which has been granted fast track status from the FDA to facilitate its development as a therapy for recurrent ovarian and prostate cancers (Silasi et al., 2009). Other compounds: triphendiol, NV-143 and NV-128, which are further derivatives of phenoxodiol, are still investigational drugs.

Phenoxodiol was intended for usage in a therapy of early-stage prostate cancer, late-stage, hormone-refractory prostate cancer, early stage cervical and vaginal cancer, chemo-resistant and chemoresistant ovarian cancer. It was shown to induce death of cancer cells through pleiotropic mechanism: inhibition of the anti-apoptotic proteins FLIP and IAP and the increase of the pro-apoptotic protein BAX, inhibition of tyrosine kinases and topoisomerase II in a dose-dependent manner (Alvero et al., 2006; Kluger et al., 2007; Constantinou et al., 2002, Sapi et al., 2004]. Phenoxodiol was tested in phase 3 OVATURE trial in women with recurrent ovarian cancer. No statistically significant improvement in its primary (progression-free survival) or secondary (overall survival) endpoints were found, so the study was terminated (Howes et al., 2011).

Triphendiol is tested for use against pancreas and bile duct cancers and found to act synergistically with gemcitabine (Saif et al., 2009). NV-143 was found to be effective against multiple melanoma cell lines, while NV-128, demonstrated efficacy in monotherapy and as a chemosensitizer in non-small cell lung carcinoma (NSCLC) cell lines. Interestingly, NV-128 induced cell death via a caspase-independent pathway and autophagic cell death (Alvero et al., 2009). In summary, triphendiol, NV-143 and NV-128 exhibited a good safety profile, they were well tolerated and non-clastogenic. Effective inhibition of tumor proliferation was shown in animal models after oral administration of the tested drugs.

3.5.5 Synthetic glycoconjugates of genistein interacting with mitotic spindle
The effectiveness of microtubule-targeting drugs for the treatment of a broad range of human cancers has been shown in many clinical studies. The search for compounds with similar mechanisms of action to taxanes or vinca alkaloids resulted in the discovery of a number of novel microtubule-targeting drugs, the majority of which are natural products. Although, genistein was recently shown to interact with interphase microtubules (Mukherjee et al., 2010), its clinical use as an antimitotic drug is rather doubtful due to very high concentration necessary to achieve this effect. However, it seems that chemical
derivatization can help to obtain novel compounds exhibiting increased affinity to microtubules. We found, among the glycosidic derivatives described by Polkowski et al. (2004), that the compound named G21 (Fig. 6), which inhibited cell proliferation at the concentration 10 times lower than genistein, interacted with mitotic spindle (Rusin et al., 2009).

This compound caused remarkable mitotic block at the concentration inhibiting cell proliferation by half, compared to the control. Our observations were recently confirmed by others (Ahmed et al., 2011). Earlier studies shown that the structure of G21 molecule was stable, it did not hydrolyze under in vitro cell culture conditions (Ksycińska et al., 2004) and its toxicity against cancer cells was higher than against normal ones (Popiołkiewicz et al., 2005). The continuation of our work on glyconjugates of genistein exhibiting antimitotic activity pointed another molecule, called Ram3 (Fig. 6), as a potent agent affecting mitotic spindle (Rusin et al., 2011) and leading to apoptotic cell death.

![Fig. 6. Structure of genistein glycoconjugates showing antimitotic activity. A. G21, B. Ram3.](image)

### 4. Conclusion

Many studies concerning the biological properties of genistein analogues demonstrated that the modification of the parent isoflavone may lead to compounds exhibiting not only enhancement of the activities already known, but also revealed novel properties, not observed for the parent compound. The biological activity of the synthetic derivatives of genistein, briefly summarized in this review, indicate that, at least some of them can be viewed as important lead compounds for further modifications. Although most of the derivatives have the status of investigational or experimental drugs, multiple identified molecular targets of genistein identified so far give hope that clinically applicable and target-specific genistein derivatives may appear in the future.

There are obviously open questions, which diseases such genistein derivatives would be addressed for and whether they would be therapeutically useful in monotherapy or - what seems more probable - in combination therapies.

### 5. Acknowledgment

We would like to acknowledge our colleagues for working together on the glycoconjugates of genistein with antimitotic properties, which is our small contribution into field of genistein derivatives for medicinal applications: Professor Grzegorz Grynkiewicz and Professor Wiesław Szęja for all inspiring discussions and designing the glycoconjugates of genistein, Ms Jadwiga Zawisza for chemical syntheses and all colleagues who carried cytotoxicity assays, dr Magdalena Glowala-Kosinska, Dr Agnieszka Gogler, Ms Aleksandra Gruca and Ms Katarzyna Kuja.

www.intechopen.com
6. References


www.intechopen.com


www.intechopen.com


Wimalawansa, S.J. (2000). Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss:


www.intechopen.com
Worldwide, soybean seed proteins represent a major source of amino acids for human and animal nutrition. Soybean seeds are an important and economical source of protein in the diet of many developed and developing countries. Soy is a complete protein, and soy-foods are rich in vitamins and minerals. Soybean protein provides all the essential amino acids in the amounts needed for human health. Recent research suggests that soy may also lower risk of prostate, colon and breast cancers as well as osteoporosis and other bone health problems, and alleviate hot flashes associated with menopause. This volume is expected to be useful for student, researchers and public who are interested in soybean.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
